Long-term reverse remodeling with cardiac resynchronization therapy: results of extended echocardiographic follow-up

David Verhaert1, Richard A Grimm, Chirapa Puntawangkoon

  • 1Department of Cardiovascular Medicine, Section of Cardiac Imaging, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

Insights

Cardiac resynchronization therapy (CRT) significantly reduces left ventricular end-systolic volume index (LVESVi) within 6 months in patients with uneventful survival. This improvement is generally maintained long-term, unlike in patients with adverse outcomes.

Area of Science:

  • Cardiology
  • Heart Failure Management
  • Cardiac Resynchronization Therapy

Background:

  • Reverse remodeling is key to improving outcomes in heart failure.
  • Understanding long-term remodeling post-CRT is crucial for patient management.

Purpose of the Study:

  • To analyze the long-term effects of cardiac resynchronization therapy (CRT) on left ventricular remodeling.
  • To account for patient loss due to disease in the analysis of CRT outcomes.

Main Methods:

  • Analysis of 313 patients undergoing CRT with echocardiographic follow-up.
  • Longitudinal data analysis of left ventricular end-systolic volume index (LVESVi).
  • Adjustment for patient attrition due to mortality, transplantation, or LVAD implantation.

Main Results:

  • Patients with uneventful survival showed a significant decrease in LVESVi within 6 months.
  • LVESVi remained stable in uneventful survival patients beyond 6 months.
  • Adverse outcomes were associated with persistent or increased LVESVi despite CRT.

Conclusions:

  • CRT induces significant reverse remodeling within 6 months in survivors.
  • Long-term CRT response is characterized by sustained LVESVi reduction in uneventful survival cases.
  • Left ventricular dilation persists in CRT patients experiencing adverse outcomes.
Abstract

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...